Genprex, Inc.

NasdaqCM:GNPX Voorraadrapport

Marktkapitalisatie: US$7.7m

Genprex Beheer

Beheer criteriumcontroles 3/4

Genprex's CEO is Ryan Confer, appointed in Sep 2016, has a tenure of 8.17 years. directly owns 0.19% of the company’s shares, worth $14.41K. The average tenure of the management team and the board of directors is 3.2 years and 4.3 years respectively.

Belangrijke informatie

Ryan Confer

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO8.2yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn3.2yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Jan 31
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Oct 12
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27
We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Analyse CEO-vergoeding

Hoe is Ryan Confer's beloning veranderd ten opzichte van Genprex's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023n/an/a

-US$31m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$1mUS$393k

-US$24m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$345k

-US$21m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$1mUS$351k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$300k

-US$11m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$2mUS$225k

-US$12m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017US$585kUS$180k

-US$3m

Compensatie versus markt: Insufficient data to establish whether Ryan's total compensation is reasonable compared to companies of similar size in the US market.

Compensatie versus inkomsten: Ryan's compensation has been consistent with company performance over the past year.

CEO

Ryan Confer (42 yo)

8.2yrs

Tenure

US$1,135,943

Compensatie

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer has serv...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mark Berger
Chief Medical Officer3.2yrsUS$947.11k0.048%
$ 3.7k
Ryan Confer
President8.2yrsUS$1.14m0.19%
$ 14.4k
David Schloss
Senior Vice President of Human Resources2.8yrsgeen gegevensgeen gegevens
Thomas Gallagher
Senior Vice President of Intellectual Property & Licensing4.2yrsgeen gegevensgeen gegevens
Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Quality1.3yrsgeen gegevensgeen gegevens
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datageen gegevensgeen gegevens

3.2yrs

Gemiddelde duur

Ervaren management: GNPX's management team is considered experienced (3.2 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Ryan Confer
Presidentless than a yearUS$1.14m0.19%
$ 14.4k
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datageen gegevensgeen gegevens
Brent Longnecker
Independent Director4.7yrsUS$161.61k0.024%
$ 1.9k
James E. Rothman
Strategic Advisor to the Board of Directors12.3yrsgeen gegevensgeen gegevens
Pasi Antero Janne
Member of Scientific & Medical Advisory Boardno datageen gegevensgeen gegevens
George Peoples
Member of Clinical Advisory Board3.8yrsgeen gegevensgeen gegevens
Shu Kam Mok
Member of Scientific & Medical Advisory Boardno datageen gegevensgeen gegevens
George Simon
Member of Scientific & Medical Advisory Boardno datageen gegevensgeen gegevens
William Wilson
Independent Director4.7yrsUS$151.16k0%
$ 0
Jose Antonio Toscano
Independent Non-Executive Chairman4.7yrsUS$161.61k0%
$ 0
George Gittes
Member of Scientific Advisory Board4yrsgeen gegevensgeen gegevens
Michael Morse
Member of Clinical Advisory Board3.8yrsgeen gegevensgeen gegevens

4.3yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: GNPX's board of directors are considered experienced (4.3 years average tenure).